Articles
-
1 week ago |
fiercebiotech.com | James Waldron
Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder. The asset in question, dubbed GLM101, is a mannose-1-phosphate replacement therapy.
-
1 week ago |
fiercebiotech.com | James Waldron
Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small, single arm study of patients with brain cancer. The phase 2 Ipax-Linz trial enrolled eight patients with recurrent high-grade glioma, who received adaptive intravenous dosing of TLX101, a radiation therapy that targets L-type amino acid transporter (LAT1), along with external beam radiation therapy (EBRT).
-
1 week ago |
fiercebiotech.com | James Waldron
Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its original focus of fertility and spinning off the cancer business. Before the company's April 14 announcement, the NAYA organization had been divided between NAYA Oncology and NAYA Fertility, two groups focused on bispecific antibodies and fertility care clinics, respectively.
-
1 week ago |
fiercebiotech.com | James Waldron
Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 asthma study. The French pharma has been evaluating three doses of the drugs an add-on therapy in the TIDE-Asthma trial of 437 patients with moderate-to-severe asthma. The primary endpoint of the study was the annualized rate of severe asthma exacerbations at week 48.
-
1 week ago |
fiercebiotech.com | James Waldron
Ironwood Pharmaceuticals is mulling its options after the FDA demanded another phase 3 trial before it will make an approval decision on the biopharma’s long-acting GLP-2 analog. The drug developer initiated a rolling approval application in January for the candidate, called apraglutide, for the treatment of short bowel syndrome (SBS) patients who are dependent on parenteral support (PS), a necessary intravenous treatment for people with severe organ failure conditions.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 10K
- DMs Open
- No
Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here... https://t.co/ir4daAfdFx
For this week's @FierceBiotech podcast, I caught up with @novonordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer https://t.co/82yunwgPuE
My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)
Jefferies London Healthcare Conference, which until last year had been a relatively cozy affair, has seemingly become a victim of its own success. Is the meeting the next JPM? https://t.co/Z1FVDYQX4e
